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Objective. To assess the diagnostic relevance of incidental prenatal findings of sex chromosome aneuploidies. Methods. We searched
with medical subject headings (MeSHs) and keywords in Medline and the Cochrane Library and systematically screened
publications on postnatally diagnosed sex chromosomal aneuploidies from 2006 to 2011 as well as publications on incidentally
prenatally diagnosed sex chromosomal aneuploidies from 1980 to 2011. Results. Postnatally diagnosed sex chromosomal
aneuploidies demonstrated three clinical relevant domains of abnormality: physical (22–100%), behavior (0–56%), and
reproductive health (47–100%), while incidentally prenatally diagnosed sex chromosomal aneuploidies demonstrated, respectively,
0–33%, 0–40%, and 0–36%. Conclusion. In the literature incidental prenatal diagnosis of sex chromosomal aneuploidies is
associated with normal to mildly aﬀected phenotypes. This contrasts sharply with those of postnatally diagnosed sex chromosomal
aneuploidies and highlights the importance of this ascertainment bias towards the prognostic value of diagnosis of fetal sex
chromosomal aneuploidies. This observation should be taken into account, especially when considering excluding the sex
chromosomes in invasive prenatal testing using Rapid Aneuploidy Detection.
1. Introduction
Sex chromosomal aneuploidies (SCAs) are usually diagnosed
postnatally in association with specific physical, develop-
mental, and psychological health problems, diminished
fertility, or infertility (incidence 1 in 400) [1]. Prenatally, the
overall incidence of SCAs is 1 in 435 [2], depending on
the reason for referral for invasive prenatal testing. For
pregnant womenwhose unborn children are at risk for Down
syndrome (e.g., maternal age >35 years or a positive first
trimester screening result without ultrasound abnormali-
ties), the incidence of SCAs is comparable to that of Down
syndrome (1 in 300) [3], which represents 25% of all
abnormal karyotypes identified [4]. Diagnoses of SCAs in
routine prenatal invasive testing are often incidental and
present unforeseen findings to the parents, whereas their
diagnostic significance is uncertain [5]. As such, these SCAs
may be considered as nondiscretionary test information.
They are indicative of an abnormality that in the end may
not cause any relevant symptoms or only mild symptoms
such as a slightly reduced intelligence and/or a diminished
fertility. Taking into account that parents are primarily
tested to exclude Down syndrome, the diagnosis of an SCA
may elicit unforeseen dilemmas about whether or not to
terminate the pregnancy [6]. A recent study revealed that
in 36% of prenatally detected sex chromosome trisomies
these findings have resulted in pregnancy termination [7].
Early and presymptomatic diagnoses may, however, provide
opportunities for early treatment of certain health and
developmental problems and, as such, may represent an
advantageous step towards future healthcare for the child.
This latter issue has amply been discussed in the literature
[8–12].
Since molecular diagnostic technologies based on Mul-
tiplex Ligation-dependent Probe Amplification (MLPA) or
Quantitative Fluorescent Polymerase Chain Reaction (QF-
PCR) are designed for rapid aneuploidy detection (RAD) of
the most common aneuploidies (i.e., of chromosomes 13, 18,
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21, X, and Y) [13], the question of whether or not to continue
the inclusion of probes for the sex chromosomes arises,
since sex chromosome detection does not always provide
useful information to parents referred for advanced maternal
age [14]. Replacement of full karyotyping with stand-alone
RAD for chromosomes 13, 18, and 21 only, would avoid
incidental SCA findings. An advantage of early SCA detection
may provide opportunities for preventive programs aimed
at ameliorating the quality-of-life. This study consists of a
systematic literature review assessing the syndrome-specific,
health-related, quality of life (QOL) aspects of patients with
postnatally diagnosed SCAs and comparing these results with
those of prenatally incidentally diagnosed SCAs.
2. Methods: Sources, Search Strategy, and
Study Selection
2.1. Sources and Search Strategy. We performed systematic
electronic searches during the period of August 2010 until
March 2011 in Medline (PubMed) and the Cochrane
Library (Database of Systematic Reviews and the Cochrane
Pregnancy and Childbirth Group’s Trials Register) using
medical subject headings (MeSHs), filters, and keywords.
We employed a two-stage process for our searches: first,
we assessed the literature over the last 5 years (2006–2011)
aimed at gathering information about specific phenotypes
associated with postnatally diagnosed SCAs. Second, we
assessed the literature from 1980 onward aimed at gathering
information about the diﬀerence in phenotype after an
incidental prenatal detection of SCAs and the associated
phenotypes that were ascertained postnatally.
2.2. Study Selection. We used the following terms in our
PubMed literature search: sex chromosome aberrations “or”
sex chromosome disorders “or” X chromosome “or” chro-
mosome human X “or” Y chromosome “or” Turner syn-
drome “or” 45,X syndrome “or” Klinefelter syndrome “or”
47,XXY syndrome “or” Triple X syndrome “or” Trisomy
X syndrome “or” 47,XXX syndrome, and “not” Fragile X
syndrome. We used filters for publications in English dealing
with human subjects.
We prepared a PICO research query in order to focus our
search on the period 1980–2011.
PICO Research Query Used to Focus Literature Search and
Data Abstraction. How does a prenatal diagnosis of SCA
aﬀect quality of life for individuals, whether intended or not?
PICO research query:
P: fetus/child with SCA,
I: invasive prenatal diagnostic test with incidental find-
ing of fetal SCA,
C: prenatal ultrasound abnormality or postnatal diag-
nosis SCA,
O: postnatal prognosis in syndrome-specific health-
related quality of life.
The accountability for this research period is the fact
that the first study on ultrasonographically abnormal fetuses
were published around 1980.We double checked all retrieved
publications for the following MeSH inclusion criteria and
keywords: prenatal diagnosis, disease, prognosis, quality of
life, postnatal, phenotypic, prospect, prognosis, unforeseen,
unintended, and accidental. We combined all search terms
and keywords with (MeSH, tiab).
2.2.1. Inclusion Criteria (Stage 1). All publications used were
published in peer-reviewed journals listed in the Science
Citation Index. We included original articles, reviews, ran-
domized trials, cohort studies, case-control studies, case
reports, letters, expert opinions, and consensus meeting
reports dealing with either full-blown or mosaic SCA.
2.2.2. Inclusion Criteria for Publications according to the
Research Query (Stage 2). We used the criteria of stage 1,
publications concerning the incidental prenatal SCA findings
in relation to the postnatal, syndrome-specific, QOL prog-
nosis and a comparison with this prognosis for postnatally
ascertained SCAs.
2.2.3. Exclusion Criteria. We excluded all publications deal-
ing with ultrasonographic fetal abnormalities, epidemiology,
registration, or counseling issues in relation to SCAs, cyto-
genetic, or molecular technical prenatal diagnostic research
and animal studies.
2.2.4. Publication Selection for Stages 1 and 2. In both stages,
the authors (J. J. P. M. Pieters and A. J. A. Kooper) screened
the titles of all potentially relevant publications and marked
them as “included” (title clearly related to SCA and meeting
the inclusion criteria set for both stages) or “excluded”
(not related, other syndrome, or not meeting the inclusion
criteria). Next, the authors (J. J. P. M. Pieters and A. P.
T. Smits) screened the abstracts of the remaining titles,
again marking them as “included” or “excluded.” All authors
discussed the items that were unclear until they reached
agreement. Finally, we grouped all included publications by
syndrome.
3. Results
3.1. Stage 1: SCA and Syndrome-Specific Quality of Life (2006–
2011). Using the criteria set (see Methods) we retrieved 1093
potentially relevant publications from the period 2006–2011.
Specifically, we screened for issues concerning syndrome-
specific, health-related, QOL prognoses for persons exhibit-
ing SCA. This resulted in 607 selected publications dealing
with Turner syndrome (TS, n = 400), Klinefelter syndrome
(KS, n = 193), Triple X syndrome (Tr X, n = 7), or other
SCAs (n = 7); see Table 2.
3.2. Syndrome-Specific, Health-Related, Quality-of-Life Do-
mains. Based on the results, we were able to determine three
domains that could be considered the core outcome domains
in assessing the syndrome-specific QOL of patients with
SCA, that is, physical health, behaviour, and reproductive
health (Tables 1 and 2).
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Table 1: Categorization of disease-specific QOL domains related to
SCA.
Domain I: physical health
Growth and bone mineral density
Cardiovascular, metabolic, and
other disease
Autoimmune disease
Other SCA-associated health
problems
Overall disease susceptibility and
mortality
Domain II: behavior
Psychosocial functioning
Quality of life
Sexuality
Domain III: reproductive
health
Puberty
Fertility
Assisted reproduction techniques
Disease
3.2.1. Domain 1: Physical Health. Physical health was char-
acterized by abnormal growth, diminished bone min-
eral density, cardiovascular, metabolic, and other diseases,
autoimmune disease, increased cancer risk, dental problems,
otologic problems, and overall disease susceptibility and
mortality. Also, early screening and preventive programs for
health were mentioned. All SCA-related health hazards and
overall QOL were said to benefit from early recognition,
prompt diagnosis, and pharmacologic or psychosocial treat-
ment in an early stage. Other SCAs were associated with
the exacerbation of certain medical conditions relative to the
burden of these conditions among the general population.
Examples of such conditions are asthma, congenital heart
defects, and increased morbidity or mortality rate caused
by epileptic insults, cardiovascular disease, or respiratory
disease. Most health hazards were described in association
with TS and KS, while Tr X syndrome and other SCA-related
disorders were only rarely discussed in relation to domain 1.
A relevant finding was the importance of early recognition
and preventive treatment of certain health problems.
3.2.2. Domain 2: Behavior. Problematic psychosocial func-
tioning and learning capacities, diminished QOL, and
problems with relationships and sexuality were discussed
in association with SCA. Certain behavioral weaknesses
(Diagnostic and Statistical Manual of Mental Disorders
(DSM) IV: Adjustment Disorder with Mixed Disturbance
of Emotions and Conduct) and limited skills associated
with specific brain asymmetries, especially in TS and KS,
have been found, and a high body mass index has been
related to a negative body attitude. Early psychoeducational
support and medical therapy were found to positively aﬀect
the patients concerned. Health aspects, infertility, aberrant
stature, and psychosocial disabilities negatively influenced
the QOL. Positive eﬀects of early growth hormone and
estrogen treatment on the psychosocial functioning and self-
esteem of girls with TS and of testosterone treatment on the
pubertal changes, behavior, and sexuality of boys with KS
have been reported. Domain 2 was a focal point of attention
both for individuals with Tr X syndrome and those with
other SCAs. Attention deficit disorders, autism spectrum
disorders, mood disorders, and tic disorders were found.
3.2.3. Domain 3: Reproductive Health. A variety of aspects
of fertility and endocrinology were denoted as problematic
in TS and KS, including problematic puberty or abnormal
gonadal development (TS: n = 25 and KS: n = 33 reports,
resp.), but there were very little reports of infertility asso-
ciated with other SCAs. Although assisted reproduction
techniques (ART) created new possibilities of procreation,
associated risks were mentioned.
Most patients with a nonmosaic SCA karyotype (TS
and KS) were infertile, whereas those with mosaicisms were
usually fertile. Also here, early gamete cryopreservation and
ART have made procreation possible, but medical hazards
and the risk of transmission of aneuploidy to the next
generation have been discussed.
Domain 1 (physical health) was mostly discussed in the
SCA literature in general and, specifically, in conjunction
with all types of SCA. Behavior was not a prominent issue,
and reproductive health was mostly discussed in relation to
KS. For further details about the incidence of the domains
discussed per syndrome in the period 2006–2011, see Table 2
and Figure 1; the study selection process is shown in Figure 2.
3.3. Stage 2: Incidental Prenatally Diagnosed SCA and Post-
natally Ascertained SCA, 1980–2011. We searched PubMed
and the Cochrane Library for eligible publications about the
incidental prenatal diagnosis of SCA with special attention
to our PICO research query. We identified 6345 potentially
relevant SCA publications using the MeSH terms, search
conditions, and filters described in the Methods section. We
excluded publications that did not meet all our inclusion
criteria. We included 1278 publications that were subjected
to peer review with regard to the relevance of an incidental
intrauterine SCA finding for the long-term developmental
prognosis. Finally, we included 32 publications for abstract
screening and categorization by domain. After abstract
screening, 21 potentially relevant publications were kept,
seven of which were selected after full text screening (Table 3
and Figure 3) relating to the PICO query: an incidental
prenatal diagnosis of SCAs, description of the associated phe-
notype and the syndrome-specific quality-of-life aspects for
postnatal life, and a comparison with postnatally ascertained
SCAs.
(1) Wheeler et al. [15] compared the postnatal phe-
notypes of six incidental prenatally diagnosed 45,X/46,XY
fetuses of couples with an increased risk of a chromosome
abnormality. The postnatally diagnosed children were all
phenotypically abnormal in domain 3, whereas the inci-
dentally prenatally diagnosed fetuses all developed into
phenotypically normal boys.
(2) Pettenati et al. [16] reported a comparison of three
incidental prenatally diagnosed cases with 45,X/47,XYY mo-
saicisms with four cases diagnosed postnatally with similar
mosaicisms. The three incidental prenatally diagnosed cases
were all physically normal at birth, whereas the postnatally
diagnosed cases all exhibited phenotypic anomalies (which
had been the reason for karyotyping).
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Table 2: Number of publications on SCA in the period 2006–2011, syndrome-specific quality-of-life domains.
Publications per
domain
45,X
(n,%)
45,X mosaic
(n,%)
47,XXY
(n,%)
47,XXY
mosaic
(n,%)
47,XXX
(n,%)
47,XXX
mosaic
(n,%)
Other SCA
(n,%)
Other SCA mosaic
(n,%)
I: physical health
(n = 446) 295 (78.5%) 21 (87.5%) 117 (61.6%) 2 (66.7%) 4 (66.7%) — 5 (100%) 2 (100%)
II: behavior
(n = 73) 41 (10.9%) — 31 (16.3%) — 1 (16.7%) — — —
III: reproductive
health (n = 88) 40 (10.6%) 3 (12.5%) 42 (22.1%) 1 (33.3%) 1 (16.7%) 1 (100%) — —
N = 607 376 (100%) 24 190 (100%) 3 6 (100%) 1 5 (100%) 2
N : number of publications found in the period 2006–2011.
(%): percentage of total number of publications on that type of SCA.
0
0
88
36
47
17
72
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8
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SCAs: incidental prenatal versus postnatal diagnosis
Figure 1: Publications on SCA, 1980–2011, syndrome-specific quality-of-life domains incidental prenatal detection versus postnatal diag-
nosis.
(3) Hsu [17] reviewed many studies on Y chromosome
aneuploidies (except nonmosaic 47,XYY), going back to
publications of as early as 1961 and reported in this elab-
orate review on 600 cases with mosaicisms for genotype-
phenotype correlations. Of these, 93 were incidentally pre-
natally diagnosed, while all the other cases were postnatally
diagnosed because of phenotypic anomalies. All postnatally
diagnosed cases were phenotypically abnormal (which had
been the reason for karyotyping), while 67–97% of the pre-
natally diagnosed cases exhibited a normal male phenotype
at birth.
(4) Koeberl et al. [18] reported on 12 incidental pre-
natally diagnosed 45,X/46,XX patients and compared the
outcomewith 41 postnatally diagnosed girls. They concluded
that, although a certain ascertainment bias did exist, the
prevalence of a 45,X/46,XX mosaicism was 10 times higher
among the group diagnosed prenatally as compared to post-
natally diagnosed TS patients. Absence of hydrops fetalis may
account for themilder phenotype of the prenatally diagnosed
group.
(5) Gunther et al. [19] compared 16 incidental prenatally
diagnosed patients with TS with 72 traditionally diagnosed
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Publications identified through database searches (n = 1093)
Turner syndrome (n = 729)
Triple X syndrome (n = 14)
Other SCA (n = 21)
Publications included for judging domains (n = 607)
Domains
I (%) II (%) III (%)
Turner syndrome (n = 376) 78.5 10.9 10.6
87.5 — 12.5
Klinefelter syndrome (n = 190) 61.6 16.3 22.1
66.7 —
Triple X syndrome (n = 6) 66.7 16.7 16.7
— — 100
Other SCA (n = 5) 100 — —
100 — —
Publications excluded after title
screening
(n = 486)
animal studies, not listed in
studies, not related to research query)
33.3
Klinefelter syndrome (n = 329)
{Search terms: Turner syndrome [MeSH, tiab] or 45, X [MeSH, tiab]}
{Search terms: Klinefelter syndrome [MeSH, tiab] or 47, XXY [MeSH, tiab]}
{Search terms: Triple X syndrome [MeSH, tiab] or Trisomy X
syndrome [MeSH, tiab] or 47, XXX [MeSH, tiab]}
Mosaic 45, X (n = 24)
Mosaic 47,XXY (n = 3)
Mosaic 47,XXX (n = 1)
Mosaic (n = 2)
(Reasons: duplicates, not English, not SCA,
Science Citation Index, technical PND
Figure 2: Prisma Flowchart of systematic study selection (stage 1: 2006–2011).
children (typical fetal anomalies on ultrasound or postnatal
clinical features). The incidental group exhibited signifi-
cantly fewer phenotypic TS features than the traditional
group. The authors concluded that a significant ascertain-
ment bias does exist in our understanding of TS, with
important implications for prenatal counseling in case no
fetal abnormalities are found.
(6) Zeger et al. [20] compared phenotype data from
55 postnatally diagnosed 47,XXY boys with those from 35
prenatally diagnosed 47,XXY boys and found no significant
diﬀerences between the two groups. Invariably, all features
occurred comparable in both groups.
(7) Girardin et al. [21] reported a comparison of clinical
symptoms of adolescents with KS after incidental prenatal
diagnosis (n = 11) with those of adolescents diagnosed
because of an abnormal phenotype (n = 17). They con-
cluded that there were some diﬀerences between the two
groups with respect to the presence of gynaecomastia,
school delay, and testosterone substitution. Although these
diﬀerences were not significant, the incidence of phenotypic
problems in the postnatally diagnosed group was somewhat
higher than in the incidental prenatally diagnosed group.
The incidences diﬀered significantly in comparison with the
general population.
3.4. Conclusions of Stage 2. Physical health (domain 1)
was abnormal for 0–33% of those who were diagnosed
incidentally prenatally, whereas it was abnormal for 22–
100% of those who were diagnosed postnatally. The behavior
(domain 2) was abnormal for 0–40% of the incidental
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Table 3: Publications on the incidental prenatal diagnosis versus postnatal diagnosis of SCA in period 1980–2011. Case-control studies,
clinical comparison, and outcome data.
Author, year
Prenatal incidental diagnosis SCA outcome
of domains
Postnatal diagnosis SCA outcome of
domains
Type SCA
(1) Wheeler et al.,
1988 [15]
6 pregnancies, 3 term, 1 premature delivered
infants, 1 termination, 1 intrauterine death:
4 healthy children, 2 fetuses normal on
autopsy
Domain I:
100% normal
Domain II:
100% no mental retardation
Domain III:
100% Normal reproductive fertility and
normal genitalia
9 children with abnormal intern/extern
genitalia, 7 children with ambiguous
genitalia at birth, 2 children with primary
amenorrhea at age 17
Domain I:
22% short stature, webbed neck
Domain II:
100% no mental retardation
Domain III:
88%: ambiguous genitalia, changed sexual
assignment, rudimentary phallus, urogenital
sinus, hypospadias, undescended testes;
22%: primary amenorrhea
45,X/46,XY
mosaicism
(2) Pettenati et
al., 1991 [16]
3 prenatally detected cases; clinical
comparison with the postnatally detected
cases
Domain I:
Two phenotypically normal term born
infants, 1 posttermination normal male
fetus on autopsy
Domain II:
Normal
Domain III:
Normal external male genitalia in both
children; fetus with normal position of
testes, normal penis, and scrotal
development
4 postnatally detected cases, clinical
comparison with the prenatally detected
cases
Domain I:
All had phenotypic abnormalities: short
statue, short limbs, cubitus valgus, nevi,
epicanthical folds, depressed nasal bridge,
micrognathia, low hair implantation,
webbed neck, shield chest, posteriorly
rotated ears
Domain II:
One child developmental delay
Domain III:
All children had genital abnormalities:
ambiguous genitalia, mixed gonadal
dysgenesis, streak gonads, hypospadias,
small penile length
45,X/47,XYY
mosaicism
(3) Hsu, 1994
[17]
Phenotype of 93 prenatally diagnosed cases,
liveborn and abortuses
Domain I:
Not discussed
Domain II:
Not discussed
Domain III:
67–97% normal gonads or genitalia
phenotype of 503 postnatally diagnosed
cases
Domain I:
0–25% phenotypically abnormal stature
Domain II:
Not discussed
Domain III:
66–100% abnormal gonads or genitalia
Y chromosome
aneuploidy
(except
nonmosaic
47,XYY)
(4) Koeberl et al.,
1995 [18]
12 prenatally diagnosed cases
Domain I:
All (100%): normal growth, 3 (25%) health
problems: ASD, ptosis, dysplastic kidneys
Domain II:
8% mental retardation
Domain III:
10 (83%): normal; 2 (17%): labial fusion,
urogenital sinus
41 postnatally diagnosed patients
Domain I:
22–53% malformations or phenotypic
problems (edema, cardiac, renal otologic,
gastrointestinal)
Domain II:
8% developmental delay
Domain III:
72% no spontaneous menarche
45,X/46,XX
mosaicism
(5) Gunther et al.,
2004 [19]
16 incidentally diagnosed cases
Domain I:
31% heart defects, 25% renal anomalies,
length/height deficit (−1.1 SDS), weight
deficit (−1.0 SDS)
Domains II and III:
Not discussed
72 traditionally postnatal diagnosed cases
Domain I:
64% heart defects,19% renal anomalies,
length/height deficit (−1.7 SDS), weight
deficit (−1.7 SDS)
Domains II and III:
Not discussed
45,X
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Table 3: Continued.
Author, year
Prenatal incidental diagnosis SCA outcome
of domains
Postnatal diagnosis SCA outcome of
domains
Type SCA
(6) Zeger et al.,
2008 [20]
35 prenatally diagnosed boys
Domain I:
Tall stature, hypotonia, increased BMI
Domain II:
Speech and reading therapy
Domain III:
Below average size penis and testes, low
testosterone level, low inhibin B and AMH
levels, elevated FSH and LH levels
20 postnatally diagnosed boys
Domain I:
tall stature, hypotonia, increased BMI
Domain II:
Speech and reading therapy
Domain III:
Below average size penis and testes, low
testosterone level, low inhibin B and AMH
levels, elevated FSH and LH levels
no significant diﬀerences with prenatal
group
47,XXY
(7) Girardin et
al., 2009 [21]
11 prenatally diagnosed patients
Domain I:
Gynaecomastia 33%, BMI, height: normal
Domain II:
School delay 40%
Domain III:
All had spontaneous puberty, testosterone
substitution 36%
17 postnatally diagnosed patients
Domain I:
Gynaecomastia 77%, BMI, height: normal
Domain II:
School delay 56%
Domain III:
All had spontaneous puberty, testosterone
substitution 47%
47,XXY
prenatally diagnosed patients, while the behavior was abnor-
mal for 0–56% of the postnatally diagnosed patients. The
reproductive health (domain 3) was problematic for 0–36%
of the incidental prenatally diagnosed patients, whereas it
was problematic for 47–100% of the postnatally diagnosed
patients (Table 3, Figure 3).
Four of seven publications regarding the incidental
prenatal diagnosis of SCAs dealt with mosaic SCAs, which
resulted in normality in the domains of physical health
(100%), behavior (100%), and reproductive health (67–
100%). For nonmosaic cases, the normality results were:
physical health, 67–75%; behavior, 60–100%; reproductive
health, 64–83%. For postnatally ascertained SCAs, the
mosaicism-related normality results were: physical health, 0–
47%; behavior, 75–100%; reproductive health, 0–34%, while
for nonmosaic cases, the normality results were: physical
health, 0–36%; behavior, 0–44%; reproductive health, 0–
53%.
4. Discussion
A putative change in prenatal diagnosis policy from full
karyotyping to stand-alone, rapid aneuploidy detection
(RAD) with the standard inclusion of probes for the sex
chromosomes needs to be assessed carefully. The purpose of
this paper was to reveal the clinical relevance of a diagnosis of
SCA for the postnatal quality of life (QOL) of symptomatic
individuals and for those in whom the prenatal diagnosis was
an incidental finding. First, we assessed the SCA literature
of the last 5 years, in order to gather information about
the specific, phenotypic, and clinical problems associated
with postnatal SCA detection. By doing so, we found
that these publications all addressed one or more domains
of syndrome-specific health. Next, we assessed whether
the phenotypes of patients with SCA were comparable,
irrespective whether the diagnoses were made postnatally or
prenatally without any ultrasonographic abnormalities, due
to an incidental finding. To this end, we screened all SCA
literature between 1980 and 2011. We used 1980 as a starting
point since the first studies of fetal ultrasound abnormalities
that were associated with a genetic syndrome were published
around that time [22].
We found in our first literature search that physical health
(domain 1) is by far most often discussed (74%), followed by
reproductive health problems (domain 3, 14%) and behavior
(domain 2, 12%); see Tables 1 and 2. Problematic physical
health is an important issue for patients with an SCA. It man-
ifests itself as disturbances in growth or bone mineral density
and cardiac, autoimmune, and other diseases, and it certainly
influences the QOL. Many publications dealing with domain
1 mentioned possible early preventive measures. Timely
screening and treatment may significantly improve the QOL
of patients with certain very health-menacing conditions
such as abnormal growth, diminished bone mineral density,
and cardiovascular problems. Early detection of SCA-related
problems varied between domains. Some authors have
elaborated on the minimal negative side eﬀects of lifelong
hormonal treatment, but it is clear that the positive eﬀects
of this treatment far exceed the potentially negative eﬀects
[23, 24]. Apparently, reproductive health problems and
behavioral abnormalities trouble these patients to a much
lesser extent than physical health problems. Early preventive
management has been described; for example, induction
of puberty and breast development in TS and technical
advances in ART increasingly permit parenthood. We are
aware of the fact that the number of selected publications
is not automatically a measure of its importance, but its
frequency is of note.
In the second stage of our literature study, we focused on
the impact of the incidental finding of a prenatal SCA on
the postnatal outcome. The selected publications report on
comparisons of patients who were incidentally prenatally
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Publications identified through database searches
n = 6345
Publications included after keyword search
n = 1278
Incidental: n = 13
Accidental: n = 7
Disease: n = 834
Prognosis: n = 292
Prognostic: n = 26
Prospect: n = 4
Quality of life: n = 44
Postnatal: n = 58
Phenotypic: n = 272
Publications excluded after title screening: n = 1246
Publications included for abstract screening
n = 32
Excluded: n = 11
Publications included for full text screening
n = 21
Excluded: n = 14
Publications included, according to research query
n = 7
(Reasons: duplicates, not English, not SCA, animal studies, not listed in Science Citation
Index, technical PND studies, not related to research query)
Figure 3: Flow diagram of systematic literature search of SCA, 1980–2011: phenotype and health of incidental prenatal diagnosis versus
postnatal diagnosis.
diagnosed with patients who were diagnosed through tradi-
tional postnatal karyotyping (either nonmosaic or mosaic).
In six out of seven publications, the overall phenotypic
outcomes aﬀected incidentally prenatally diagnosed SCA
patients significantly less than those who were postnatally
diagnosed and karyotyped because of phenotypic abnormal-
ities. In one publication [20], no significant diﬀerences in
certain phenotypic characteristics were noted after prenatal
or postnatal diagnosis.
It is well known that certain fetal ultrasonographic
abnormalities are associated with a poor prognosis for the
child after birth, because they reflect early disturbances in
organ functioning [18]. Genetic mosaicisms are known to
be related to mild or even complete lack of phenotypic
features, and those aﬀected may go through life without
ever knowing they carry a genetic abnormality [21, 25].
Saenger’s review [26] showed that most prenatal diagnoses
of TS occur by chance after routine invasive procedures for
advanced maternal age, and the phenotypes of these women
are usually less pronounced [19]. Those with TS detected by
ultrasound (increased nuchal translucency or fetal hydrops)
exhibit a high rate of spontaneous fetal loss or associated
cardiac or renal disease [18, 27]. Bondy [10] discusses the
fact that incidentally diagnosed TS in prenatal diagnostic
tests for advanced maternal age lead to termination of most
of these pregnancies, and that the ability to assess clinical
outcome is limited. High termination rates for incidentally
diagnosed TS reflect overrated pessimistic views, as the
phenotype of someone with an incidentally ascertained TS
is compared with the phenotypic problems of those who
are postnatally diagnosed, or prenatally diagnosed because of
fetal abnormalities. Only 10% of those with KS are diagnosed
prenatally, another 25% are diagnosed during childhood or
adolescence, and 65% remain undiagnosed [28]. KS is the
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most frequent genetic cause of infertility [29, 30] (11% of
azoospermic men), and parents often report frustration with
the consequences of a delay in diagnosis [31].
Publications on the diagnosis of Tr X syndrome did not
address its incidental prenatal finding and the subsequent
clinical consequences. A recent literature review of Tr X
[32] reports mainly personality and behavioral problems and
finds that many of the studies reviewed were “biased because
of referral bias.” Furthermore, the incidental prenatal finding
of Tr X is discussed only in terms of termination rates
and intercultural diﬀerences. The author concludes that Tr
X syndrome is not rare, but often remains undiagnosed.
Approximately 20% of other SCAs have higher-grade chro-
mosome aneuploidies (e.g., 48,XXXY) ormosaicisms and the
associated clinical health issues are usually very mild.
To the best of our knowledge, this study for the first
time categorizes the abundant SCA literature into three
syndrome-specific, QOL-related domains of health. This
categorization provides a way to judge the importance of
phenotypic problems of an incidental prenatal ascertainment
of SCA relative to a postnatal ascertainment of SCA.
However, we acknowledge that even if there is an abundance
of publications about the clinical implications of SCA for
the aﬀected individual, there is little literature that compares
the diﬀerence in QOL prognoses for incidental prenatally
diagnosed patients to those diagnosed postnatally. Despite
this limitation, however, we have endeavored to review the
literature in a way that is helpful to professionals who wish
to use this information in counseling and decision-making
processes.
Routine prenatal testing procedures with the standard
diagnostic outcome of fetal gender oﬀer a unique opportu-
nity for early prevention and management of SCA-related
disease, psychological issues, and fertility issues. This benefit
is evident from the professional point of view, but it
should be balanced against the possible negative impact of
this unexpected diagnosis for the future child. Incidental
prenatal diagnosis of an SCA may cause stigmatization and
possible damage to the child’s self-esteem or distortion of
the family’s perception of the child. Indeed, parents may
consider termination of the pregnancy while being uncertain
about the prognosis for the child [33, 34]. Molecularly
targeted testing through RAD enables the exclusion of the
sex chromosomal markers, thus avoiding unexpected sex
chromosome-related SCAs. A discussion about this policy
has been published [35]. It is considered a more or less
acquired right in routine prenatal practice that pregnant
women can be informed about the sex of their unborn
children if they wish to know. However, ultrasonography can
also determine fetal gender with high accuracy (98.3%) at
13 weeks of gestation [36], and an almost 100% accuracy is
achieved around 20 weeks of gestation [37].
5. Conclusion
Early knowledge of an SCA could help the parents and their
child to adapt to the consequences of the corresponding
syndrome in a timely fashion rather than having the info-
rmation presented at puberty or even a later stage in life.
This fact must be balanced against the ethical concerns about
the diagnosis of a genetic condition with an uncertain prog-
nosis. This paper shows that, in the medical literature, the
syndrome-specific QOL of patients with an SCA contrasts
sharply between postnatal and incidental prenatal diagnoses
for the threemajor domains of health. Phenotypic abnormal-
ities in prenatal or postnatal life were found to be associated
with significantly more severe clinical consequences. In
contrast, the absence of fetal abnormalities in incidental
prenatal diagnoses was found to be associated with a normal
to mildly aﬀected phenotype, and, as such, a significant
ascertainment bias may exist in our understanding of SCA.
Although it seems rather obvious that the outcome of a
child with an incidental discovery of a sex chromosome
abnormality is better than one who is diagnosed postnatally,
this review of the literature since 1980 shows that counselors
may reassure the parents in the knowledge that indeed all
studies until now support this conclusion.
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